An Overview of Cannabidiol.
| Autor: | Sideris A; From the Department of Anesthesiology, Critical Care and Pain Medicine, Hospital for Special Surgery, New York, New York.; Department of Anesthesiology, Weill Cornell Medicine, New York, New York.; HSS Research Institute, New York, New York., Doan LV; Department of Anesthesiology, Perioperative Care, and Pain Medicine, NYU Grossman School of Medicine, New York, New York. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Anesthesia and analgesia [Anesth Analg] 2024 Jan 01; Vol. 138 (1), pp. 54-68. Date of Electronic Publication: 2023 Dec 15. |
| DOI: | 10.1213/ANE.0000000000006584 |
| Abstrakt: | Cannabidiol (CBD) is one of the most interesting constituents of cannabis, garnering significant attention in the medical community in recent years due to its proven benefit for reducing refractory seizures in pediatric patients. Recent legislative changes in the United States have made CBD readily available to the general public, with up to 14% of adults in the United States having tried it in 2019. CBD is used to manage a myriad of symptoms, including anxiety, pain, and sleep disturbances, although rigorous evidence for these indications is lacking. A significant advantage of CBD over the other more well-known cannabinoid delta-9-tetrahydroncannabinol (THC) is that CBD does not produce a "high." As patients increasingly self-report its use to manage their medical conditions, and as the opioid epidemic continues to drive the quest for alternative pain management approaches, the aims of this narrative review are to provide a broad overview of the discovery, pharmacology, and molecular targets of CBD, its purported and approved neurologic indications, evidence for its analgesic potential, regulatory implications for patients and providers, and future research needs. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2024 International Anesthesia Research Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|